Description

ProductAvailABIlity:InStock(deliverywithin2-3businessdays,noextrachargefordrop-shipping).

Ordering:ToplaceanorderviacreditcardorPOuseAddtoCartbutton(creatinganaccountisnotrequired).

TransfectionReagentforNCI-H358Cells(BronchioalveolarCells,CRL-5807)

• Ananoparticle-basedliposomeformulation
• Transfectionprotocolsprovidedfortransfectionofproteins,DNA,mRNA,siRNA,shRNAandmicroRNA
• TransfectionEnhancerreagentprovidedwiththekit
• Producehigherlevelofrecombinantproteinexpressionwithminimaldisruptionofnormalcellfunction
• Generatephysiologicallyrelevantdatayoucantrust
• EffectiveforplasmidDNA/siRNAco-transfection
• Easy-to-usetransfectionprotocolwithreproducIBLeresults
• Lowcytotoxicity
• DownloadinvitroNCI-H358transfectionprotocol:[PDF]
• Download NCI-H358CRISPR/Cas9transfectionprotocol:[PDF]
• DownloadPowerPointpresentationforNCI-H358transfectionkit:[PPT]
• DevelopedandmanufacturedbyAltogenBiosystems

TransfectionEfficiency:

Reagentexhibitsatleast89%transfectionefficiencyofsiRNAdelivery.TransfectionefficiencywasdeterminedbyqRT-PCR.

TransfectionProtocolandMSDS:

DownloadAltogenBiosystemsNCI_H358TransfectionProtocol:[PDF]

DownloadMSDS:[PDF]

NCI-H358CellLine:

Lungcancerisconsideredtheprimarycauseofcancerdeath,accountingfor14%ofallnewcancerdiagnosesandresponsiblefor1in4cancerfatalities,withthe5-yearsurvivalrateofonly18%,asstatedbytheAmericanCancerSociety.TheNCI-H358epithelialcelllinewasestablishedin1981byA.F.Gazdaretal.frombronchioletissueofapatientwithbronchioalveolarcarcinoma,atypeoflungcancer.Thetumortissuewasremovedpriortothepatientundergoingchemotherapy.TheNCI-H358celllinehasbeenknowntohaveadoublingtimeofroughly38hours.UltrastructuralstudiesdetectedthepresenceofClaracells.Inadditiontobeinganexcellenttransfectionhost,theNCI-H358celllineisrelevantinvitromodelforresearchonmedicaltreatmentsaddressinglungcancer.AltogenBiosystemsoffersnanoparticle-basedtransfectionreagentkitsforthiscellline.

Data:

Figure1.CyclophilinBsilencingefficiencywasdeterminedbyqRT-PCRintheNCI-H358cellstransfectedbyCyclophilinBsiRNAornon-silencingsiRNAcontrolfollowingtherecommendedtransfectionprotocol.CyclophilinmRNAexpressionlevelsweremeasured48hourspost-transfection.18SrRNAlevelswereusedtonormalizetheCyclophilinBdata.Valuesarenormalizedtountreatedsample.Dataarepresentedasmeans±SD(n=6).

Figure2.ProteinexpressionofCyclophilinBinNCI-H358cells.DNAplasmidexpressingCyclophilinBorsiRNAtargetingCyclophilinBweretransfectedintoNCI-H358cellsfollowingAltogenBiosystemstransfectionprotocol.At72hourspost-transfectionthecellswereanalyzedbyWesternBlotforproteinexpressionlevels(normalizedbytotalprotein,10µgoftotalproteinloadedpereachwell).Untreatedcellsusedasanegativecontrol.

AltogenBiosystems:
AltogenBiosystemsmanufacturerspreoptimizedtransfectionkitsforcancerresearch.Reagentsandtransfectionprotocolsareoptimizedforindividualcancercelllines.AltogenBiosystemsdevelopedtwotypesofinvivodeliverykitsforanimalresearch:Tissue-targetedreagents(deliveryintoliver,pancreas,andkidneytissues),andinvivobiodistributionreagents(PEG-Liposome,Nanoparticle,Lipid,andPolymer-basedkits).Optimizedtransfectionprotocolsprovideefficientintracellulardeliveryofproteins,DNA,andRNAmoleculesinvitroandinvivo.Readmore abouttransfectiontechnologyatAltogen’sTransfectionResource.

AltogenLabsResearchServices:

AltogenLabsprovidesGLP-compliantcontractresearchstudiesforpre-clinicalresearch,INDapplications,anddrugdevelopment.BIOLOGyCROservices include:Xenograftmodels(30+),developmentofstablecelllines,ELISAassaydevelopment,cell-basedandtissuetargetedRNAistudies,safetypharm/toxassays,andotherstudies(visitAltogenLabs.com).

VolumeOptions:

• 0.5ml(Catalog#6860)
• 1.5ml(Catalog#6861)
• 1.5mlCRISPR(Catalog#2180)
• 8.0ml(Catalog#7069)

Altogen Biosystems是一家开发和制造用于生命科学研究，药物发现和开发的转染试剂盒的生物技术公司。转染试剂盒针对特定癌细胞系和原代细胞培养进行了优化，可将生物分子有效递送到靶组织中。通过先进的试剂配方和优化的转染方案实现体外（癌细胞系）和体内（动物组织靶向试剂、癌细胞系）递送货物分子，包括质粒DNA，各种类型的RNA（mRNA，siRNA，shRNA，microRNA），蛋白质和小分子研究。

苏州蚂蚁淘代理Altogen Biosystems在中国的业务。Altogen Biosystems北京代理，Altogen Biosystems华东代理，Altogen Biosystems华北代理，Altogen Biosystems全国代理，Altogen Biosystems华南代理。